AXON
Price
$768.57
Change
-$50.12 (-6.12%)
Updated
Aug 12 closing price
Capitalization
60.34B
85 days until earnings call
EXEL
Price
$37.95
Change
+$0.54 (+1.44%)
Updated
Aug 12 closing price
Capitalization
10.22B
83 days until earnings call
Interact to see
Advertisement

AXON vs EXEL

Header iconAXON vs EXEL Comparison
Open Charts AXON vs EXELBanner chart's image
Axon Enterprise
Price$768.57
Change-$50.12 (-6.12%)
Volume$999.53K
Capitalization60.34B
Exelixis
Price$37.95
Change+$0.54 (+1.44%)
Volume$4.28M
Capitalization10.22B
AXON vs EXEL Comparison Chart in %
Loading...
AXON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXON vs. EXEL commentary
Aug 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and EXEL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 13, 2025
Stock price -- (AXON: $768.57 vs. EXEL: $37.95)
Brand notoriety: AXON: Not notable vs. EXEL: Notable
AXON represents the Aerospace & Defense, while EXEL is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXON: 146% vs. EXEL: 117%
Market capitalization -- AXON: $60.34B vs. EXEL: $10.22B
AXON [@Aerospace & Defense] is valued at $60.34B. EXEL’s [@Biotechnology] market capitalization is $10.22B. The market cap for tickers in the [@Aerospace & Defense] industry ranges from $296.53B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Aerospace & Defense] industry is $21.48B. The average market capitalization across the [@Biotechnology] industry is $1.79B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXON’s FA Score shows that 3 FA rating(s) are green whileEXEL’s FA Score has 0 green FA rating(s).

  • AXON’s FA Score: 3 green, 2 red.
  • EXEL’s FA Score: 0 green, 5 red.
According to our system of comparison, AXON is a better buy in the long-term than EXEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXON’s TA Score shows that 4 TA indicator(s) are bullish while EXEL’s TA Score has 5 bullish TA indicator(s).

  • AXON’s TA Score: 4 bullish, 6 bearish.
  • EXEL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, EXEL is a better buy in the short-term than AXON.

Price Growth

AXON (@Aerospace & Defense) experienced а -11.37% price change this week, while EXEL (@Biotechnology) price change was +1.31% for the same time period.

The average weekly price growth across all stocks in the @Aerospace & Defense industry was +0.54%. For the same industry, the average monthly price growth was +2.93%, and the average quarterly price growth was +51.71%.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.20%. For the same industry, the average monthly price growth was +21.00%, and the average quarterly price growth was +18.32%.

Reported Earning Dates

AXON is expected to report earnings on Nov 06, 2025.

EXEL is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Aerospace & Defense (+0.54% weekly)

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

@Biotechnology (+8.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXON($60.3B) has a higher market cap than EXEL($10.2B). AXON has higher P/E ratio than EXEL: AXON (189.30) vs EXEL (18.25). AXON YTD gains are higher at: 29.319 vs. EXEL (13.964). EXEL has higher annual earnings (EBITDA): 782M vs. AXON (398M). AXON has more cash in the bank: 2.37B vs. EXEL (791M). EXEL has less debt than AXON: EXEL (180M) vs AXON (2.05B). EXEL (2.23B) and AXON (2.23B) have equivalent revenues.
AXONEXELAXON / EXEL
Capitalization60.3B10.2B591%
EBITDA398M782M51%
Gain YTD29.31913.964210%
P/E Ratio189.3018.251,038%
Revenue2.23B2.23B100%
Total Cash2.37B791M299%
Total Debt2.05B180M1,137%
FUNDAMENTALS RATINGS
AXON vs EXEL: Fundamental Ratings
AXON
EXEL
OUTLOOK RATING
1..100
763
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
839
SMR RATING
1..100
5534
PRICE GROWTH RATING
1..100
556
P/E GROWTH RATING
1..100
1078
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (70) in the Biotechnology industry is in the same range as AXON (91). This means that EXEL’s stock grew similarly to AXON’s over the last 12 months.

AXON's Profit vs Risk Rating (8) in the Biotechnology industry is in the same range as EXEL (39). This means that AXON’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's SMR Rating (34) in the Biotechnology industry is in the same range as AXON (55). This means that EXEL’s stock grew similarly to AXON’s over the last 12 months.

AXON's Price Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for EXEL (56). This means that AXON’s stock grew somewhat faster than EXEL’s over the last 12 months.

AXON's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for EXEL (78). This means that AXON’s stock grew significantly faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXONEXEL
RSI
ODDS (%)
Bearish Trend 1 day ago
55%
Bullish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
57%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 1 day ago
67%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
58%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 7 days ago
65%
Declines
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 13 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
54%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
52%
View a ticker or compare two or three
Interact to see
Advertisement
AXON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGAFX85.231.16
+1.38%
American Funds Growth Fund of Amer R5
PGVFX35.180.45
+1.30%
Polaris Global Value
MFWJX17.83N/A
N/A
MFS Global Total Return R4
JNGLX65.47N/A
N/A
Janus Henderson Global Life Sciences D
RSMRX15.26N/A
N/A
RBC SMID Cap Growth R6

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.44%
JAZZ - EXEL
35%
Loosely correlated
+2.33%
TECH - EXEL
33%
Poorly correlated
+5.34%
MRSN - EXEL
32%
Poorly correlated
+1.68%
ORMP - EXEL
32%
Poorly correlated
+0.48%
AXON - EXEL
31%
Poorly correlated
-6.12%
More